Certain Common Stock of Qualtec Co.,Ltd. are subject to a Lock-Up Agreement Ending on 25-OCT-2023.
October 24, 2023
Share
Certain Common Stock of Qualtec Co.,Ltd. are subject to a Lock-Up Agreement Ending on 25-OCT-2023. These Common Stock will be under lockup for 89 days starting from 28-JUL-2023 to 25-OCT-2023.
Details:
The secondary offering by purchase and underwriting by the underwriters, Koichi Shikata, the seller and lender, and CBC Co., Ltd., a shareholder of the Company, will notify the lead managing company of the date of execution of the principal underwriting agreement. to October 25, 2023, which is 90 days after the listing (trading start) date (including the day), without the prior written consent of the lead managing company, sale of common stock of the Company (however, purchase by underwriters (Except for the sale by underwriting, the lending of the Company's common stock for the sale by way of overallotment, and the acquisition of the Company's common stock subject to the Green Shoe Option by the lead managing company). In addition, the Company will provide the lead manager with prior written notice during the period from the date of conclusion of the principal underwriting agreement to January 23, 2024, which is 180 days after the listing (trading start) date (including the day). without the consent of (Excludes offerings, stock splits and issuance of subscription rights to shares as stock options, etc.). In any of the above cases, the lead managing company has the authority to cancel all or part of the agreement at its discretion.
Qualtec Co Ltd is a Japan-based company engaged in reliability evaluation business, microfabrication business and other businesses. The Company operates through three segments. The Reliability Evaluation Business segment is engaged in environmental tests, electrical tests, reliability evaluation test consisting of vibration tests, non-defective product and defective analysis, cutting test material and polishing the cut surface, manufactures and sells testing machines. The Microfabrication Business segment is engaged in prototype and mass production laser processing for build-up boards and flexible printed boards. The Other Business segment is engaged in the detection service of genetic mutations that cause genetic diseases in dogs and cats through genetic testing, the bio business that conducts contracted testing of biomedical products such as packaging materials and syringes, and the zero innovation business of various consulting services, surface treatment technology business.